SYNERTONE (01613): The rights issue received valid acceptance of approximately 9.71%.
Joint Communication (01613) issued an announcement stating that as of the record date, the total number of shares issued is 449 million shares, while the maximum number of shares to be issued under the rights issue is 897 million shares.
SYNERTONE (01613) announced that as of the record date, the total number of issued shares is 449 million shares, while the maximum number of shares to be issued through the rights issue is 897 million shares. The board of directors announced that as of the record date, there are no ineligible shareholders, therefore, there are no unsold shares related to ineligible shareholders; and as of 15th January 2026 at 4:00pm (the deadline for subscription), the company has received a total of 6 valid applications and acceptances for provisional allotments under 6 provisional allotment notifications, involving a total of 87.1231 million shares to be issued under the rights issue, equivalent to approximately 9.71% of the total shares to be issued under the rights issue. Therefore, the subscription for the rights issue is insufficient, with 810 million shares of rights issue shares remaining unsubscribed, equivalent to approximately 90.29% of the total rights issue shares available for subscription, and compensation arrangements will be made.
The placement agent will make best efforts to encourage subscribers to subscribe for all (or as many as possible) of the unsubscribed rights issue shares by no later than 6th February 2026 at 4:00pm. Any unsubscribed rights issue shares under the compensation arrangements will not be issued by the company, and the size of the rights issue will be correspondingly reduced.
Related Articles

LINGBAO GOLD (03330): Huang Hui appointed as independent non-executive director.

LEADS BIOLABS-B(09887): Vitrakvi has been granted orphan drug designation (ODD) by the European Commission for the treatment of pulmonary neuroendocrine tumors.

MACAU LEGEND (01680) raised approximately HK$86.4 million from the issuance of new shares.
LINGBAO GOLD (03330): Huang Hui appointed as independent non-executive director.

LEADS BIOLABS-B(09887): Vitrakvi has been granted orphan drug designation (ODD) by the European Commission for the treatment of pulmonary neuroendocrine tumors.

MACAU LEGEND (01680) raised approximately HK$86.4 million from the issuance of new shares.

RECOMMEND

Paul Chan Says Hong Kong Has Licensed 11 Virtual Asset Exchanges, Stablecoin Licenses Expected Later This Year
22/01/2026

Ministry Of Finance And Other Departments Introduce Comprehensive Fiscal And Financial Policies To Boost Domestic Demand
22/01/2026

Capital Migration: Five Years On, An In‑Depth Analysis Of China’s 11 High‑Growth Venture Capital Tracks In 2025
22/01/2026


